Evidence map›Paper›PMID 40109859›Full record

ArticleOncology research2025

Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer.

Belardinilli Francesca, Michela DE Meo, Francesco Del Giudice, Carlo Maria Scornajenghi, Paola Gazzaniga, Ettore DE Berardinis, Luca Marino, Fabio Massimo Magliocca, Benjamin Inbeh Chung, Jan Łaszkiewicz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Belardinilli FrancescaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy.
Michela DE MeoDepartment of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy.
Francesco Del GiudiceDepartment of Maternal-Child and Urological Sciences, Sapienza University of Rome, Rome, 00161, Italy.
Carlo Maria ScornajenghiDepartment of Maternal-Child and Urological Sciences, Sapienza University of Rome, Rome, 00161, Italy.
Paola GazzanigaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy.
Ettore DE BerardinisDepartment of Maternal-Child and Urological Sciences, Sapienza University of Rome, Rome, 00161, Italy.
Luca MarinoDepartment of Mechanical and Aerospace Engineering, Sapienza University of Rome, Rome, 00161, Italy.
Fabio Massimo MaglioccaDepartment of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, 00161, Italy.
Benjamin Inbeh ChungDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jan ŁaszkiewiczUniversity Center of Excellence in Urology, Wrocław Medical University, Wrocław, 50556, Poland.
Valentina MagriDepartment of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, 00161, Italy.
Giuseppe GianniniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy.
Chiara NicolazzoDepartment of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Intravesical Bacillus Calmette-Guérin (BCG) therapy is a gold standard for patients with high-risk non-muscle invasive bladder cancer (NMIBC). Although a long-lasting therapeutic response is observed in most patients, BCG failure occurs in 30%-50% of patients and a progression to muscle-invasive disease is found in 10%-15%. Therefore, predicting high-risk patients who might not benefit from BCG treatment is critical. The purpose of this study was to identify, whether the presence of specific oncogenic mutations might be indicative of BCG treatment response. Methods: Nineteen high-grade NMIBC patients who received intravesical BCG were retrospectively enrolled and divided into "responders" and "non-responders" groups. Tissue samples from transurethral resection of bladder cancer were performed before starting therapy and were examined using a multigene sequencing panel. Results: Mutations in TP53, FGFR3, PIK3CA, KRAS, CTNNB1, ALK and DDR2 genes were detected. TP53 and FGFR3 were found to be the most frequently mutated genes in our cohort (31.6% and 26.3%, respectively), followed by PIK3CA (15.8%). In the BCG-responsive patient group, 90% of samples were found to have mutated genes, with almost 50% of them showing mutations in tyrosine kinase receptors and CTNNB1 genes. On the other hand, in the BCG-unresponsive group, we found mutations in 44.4% of samples, mainly in TP53 gene. Conclusions: Our findings suggest that a Next-Generation Sequencing (NGS) multigene panel is useful in predicting BCG response in patients with NMIBC.

Indexed as

BCG VaccineBiomarkers, TumorHigh-Throughput Nucleotide SequencingUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesTreatment OutcomeBCG VaccineBiomarkers, TumorBacillus Calmette-Guérin (BCG)MacropinocytosisMolecular profileNext-generation sequencing (NGS)Non-muscle invasive bladder cancer (NMIBC)

Identifiers

PMID40109859
PMCPMC11915050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.